SIGA Technologies, Inc. - Form 10-Q Summary
Business Context and Reporting Period
Company: SIGA Technologies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: SIGA is a bio-defense company focused on the discovery, development, and commercialization of novel products for serious infectious diseases, including biological warfare agents like smallpox and arenaviruses. The company has no commercial products and relies on government grants, contracts, and financing to fund operations.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2010 | Six Months Ended June 30, 2009 |
|---|---|---|
| Revenues | $9,521,964 | $5,934,736 |
| Operating Expenses | $15,585,600 | $11,464,579 |
| Operating Loss | $(6,063,636) | $(5,529,843) |
| Net Loss | $(8,981,079) | $(17,237,613) |
| Net Loss Per Share (Basic/Diluted) | $(0.21) | $(0.47) |
| Cash and Cash Equivalents (End of Period) | $6,540,003 | $1,608,271 |
| Short-Term Investments | $8,749,800 | $0 |
| Total Liabilities | $18,329,671 | $15,426,796 |
| Stockholders' Equity | $3,830,191 | $10,488,491 |
Cash Flow (Six Months Ended June 30, 2010):
- Net cash used in operating activities: $(4,734,855)
- Net cash used in investing activities: $(4,472,646)
- Net cash provided by financing activities: $1,251,191
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased by 60% ($3.6 million) compared to the prior year, driven by increased funding for the lead drug candidate ST-246, arenavirus drug candidates, and a new broad-spectrum antiviral drug contract.
- Expense Increases: Operating expenses rose by 36% ($4.1 million). Research and Development (R&D) expenses increased by 45% ($3.3 million) due to manufacturing costs for ST-246 and development of new candidates. Selling, General, and Administrative (SG&A) expenses increased by 9% ($342,000) primarily due to higher legal fees and insurance premiums.
- Net Loss Improvement: Net loss decreased significantly by approximately $8.3 million compared to the prior year. This improvement is largely attributable to a reduction in the non-cash loss associated with the fair value adjustment of common stock warrants (from $11.7 million in 2009 to $2.9 million in 2010).
- Liquidity Position: Cash and cash equivalents decreased by $7.9 million during the period, though the company maintained a significant position in short-term U.S. Treasury bills ($8.75 million).
Guidance, Outlook, Risks, and Unusual Items
Management Commentary & Outlook:
Management believes existing funds, combined with cash flows from government grants and contracts, are sufficient to support operations for at least the next 12 months. The company expects to continue incurring operating losses as it advances R&D programs. Success depends on commercializing R&D and securing future financing.
Unusual Items:
- Warrant Valuation: The company recorded a $2.9 million loss for the six months ended June 30, 2010, due to the increase in the fair value of common stock warrants classified as liabilities. This is a non-cash item significantly impacting net loss.
Risks and Contingencies:
- PharmAthene Litigation: PharmAthene, Inc. is suing SIGA regarding a license agreement for ST-246. PharmAthene seeks damages up to $1 billion. SIGA believes the claims are flawed and has filed a motion for partial summary judgment. Trial is expected in January 2011. No loss range can currently be estimated.
Subsequent Event:
On July 26, 2010, SIGA received $5.5 million in proceeds from MacAndrews & Forbes, LLC (M&F) under a letter agreement, issuing common stock and warrants in exchange.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $15.3 million in total liquid assets (cash + short-term investments) against the projected burn rate for the next 12 months.
- PharmAthene Litigation: Monitor the status of the partial summary judgment motion and the potential impact of the $1 billion damages claim on future operations.
- Government Funding Dependency: Assess the risk associated with 92% of revenue coming from NIH contracts and grants, and the uncertainty of future government contract awards (e.g., BARDA Smallpox RFP).
- Warrant Liability Volatility: Understand how fluctuations in stock price and volatility will continue to impact the fair value of warrants and reported net loss.
- ST-246 Development: Track progress on the commercial validation campaign and manufacturing costs for the lead drug candidate, which consumed $5.4 million in the first half of 2010.